
Xentria: Innovating cost-effective bio-pharmaceutical solutions for rare diseases and oncological conditions.
Xentria is an innovative bio-pharmaceutical company dedicated to developing cost-effective and efficacious therapeutics to address critical unmet needs in rare diseases, immunologic disorders, and oncological conditions. The company is committed to building an expansive product pipeline, with current research efforts including the XTMAB16 study focused on pulmonary sarcoidosis. Xentria emphasizes leadership through partnership, learning through authenticity, and perseverance through desire.
Xentria has made significant strides in its mission by fostering authentic life-sciences partnerships that guide drug and intellectual property development from early concepts through clinical stages and towards commercial launch. Their approach has positioned them as a key player in the biotech industry, particularly in the niche of rare diseases. The company's impact is underscored by its dedication to addressing critical health challenges and improving patient outcomes through innovative solutions.

Xsphera Biosciences

Xoc Pharmaceuticals

Xeris Biopharma Holdings

OncXerna Therapeutics
oncxerna.com

XTuit Pharmaceuticals
XRad Therapeutics

SphynKx Therapeutics

Synspira

X4 Pharmaceuticals
x4pharma.com

X-Biotix Therapeutics

Xeno Biosciences

Xontogeny
xontogeny.com

Transcera

Star Therapeutics

PleoPharma
pleopharma.com
Companies similar to Xentria include Xsphera Biosciences, Xoc Pharmaceuticals, Xeris Biopharma Holdings and OncXerna Therapeutics.
Xentria was founded in 2020.
Xentria's headquarters is located in Chicago, IL, US.
Xentria's most recent funding round was for $25M (USD) in October 2022.
As of Oct 18, 2022, Xentria has raised a total of $25M (USD).
Xentria has 13 employees as of Feb 4, 2024.